Evaluation of Changes in Pancreatic Fat Content Using Advanced MR Sequences in Diabetics on Dapagliflozin Therapy
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
- Study ID
- NCT05797935
- Phase
- PHASE4
- Status
- Completed
Conditions
- Pancreatic Lipomatosis
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 65 Years
- Healthy Volunteers
- Not accepted
Interventions
- Dapagliflozin 10mg Tab — DRUGDapagliflozin was given at a dose of 10 mg/day in one group and its effect was observed on the pancreatic fat content
Study Details
The study aimed to assess changes in pancreatic fat content in people with diabetes on dapagliflozin (SGLT2 inhibitor) and beta cell function.
Key Dates
- Start date
- Aug 1, 2021
- Status verified
- Apr 2023
- Primary completion
- Dec 20, 2022
- Completion
- Dec 31, 2022
Study Design
- Enrollment
- 50 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- OTHER
Arms
- No Intervention: Placebo groupOnly the standard drugs for type 2 diabetes were given. Dapagliflozin was not given in this group.
- Active Comparator: Dapagliflozin groupThe patients were given standard drugs for type 2 diabetes and Dapagliflozin.
Primary Outcome Measure
To assess and estimate the difference in pancreatic fat content in the patients of Type 2 Diabetes Mellitus at baseline and after taking dapagliflozin for 24 weeks [ Time Frame: 24 weeks ]